IRCT20210310050660N2 IRCT 2021-04-06 Qazvin University of Medical Sciences Evaluation of the effect of cannabidiol in the treatment of schizophrenic patients The effect of cannabidiol on positive symptoms in schizophrenic patients 2021-04-21 anticipated 40 Complete https://irct.ir/trial/55097 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this method was used from a simple randomization model of random number table and we place each participant in the intervention or control group, Blinding description: The drugs including cannabidiol and placebo drops, with the same shape and taste, were packaged with a label of herbarium at Alborz Pharmaceutical Company. The treating physician, researcher, and statistical analytics consulting who were all different people did not know any of the coding and content of each code; Therefore, this study was considered three-blind. 3 Schizophrenia. Intervention 1: Intervention group: Twenty patients with schizophrenia were treated with the common drug and cannabidiol drop. Patients received their present treatment (atypical antipsychotic risperidone) during the study and were matched in terms of dosage and type of antipsychotic drug. The intervention group was given cannabidiol drop (150 mg daily) for 6 weeks. Intervention 2: Control group: Twenty patients with schizophrenia were treated with common drug and placebo drops. Patients received risperidone during their usual course of treatment (atypical antipsychotic risperidone) and were matched in terms of dosage and type of antipsychotic drug. The control group was given placebo drops (150 mg daily) for 8 weeks. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no more information